188 related articles for article (PubMed ID: 16197343)
1. Alicaforsen therapy in inflammatory bowel disease.
Barish CF
Expert Opin Biol Ther; 2005 Oct; 5(10):1387-91. PubMed ID: 16197343
[TBL] [Abstract][Full Text] [Related]
2. Alicaforsen. Isis Pharmaceuticals.
Gewirtz AT; Sitaraman S
Curr Opin Investig Drugs; 2001 Oct; 2(10):1401-6. PubMed ID: 11890355
[TBL] [Abstract][Full Text] [Related]
3. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease.
Van Assche G; Rutgeerts P
Am J Physiol Gastrointest Liver Physiol; 2005 Feb; 288(2):G169-74. PubMed ID: 15647604
[TBL] [Abstract][Full Text] [Related]
4. Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease.
Yacyshyn BR; Barish C; Goff J; Dalke D; Gaspari M; Yu R; Tami J; Dorr FA; Sewell KL
Aliment Pharmacol Ther; 2002 Oct; 16(10):1761-70. PubMed ID: 12269969
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease.
Yacyshyn B; Chey WY; Wedel MK; Yu RZ; Paul D; Chuang E
Clin Gastroenterol Hepatol; 2007 Feb; 5(2):215-20. PubMed ID: 17296530
[TBL] [Abstract][Full Text] [Related]
6. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease.
Yacyshyn BR; Chey WY; Goff J; Salzberg B; Baerg R; Buchman AL; Tami J; Yu R; Gibiansky E; Shanahan WR;
Gut; 2002 Jul; 51(1):30-6. PubMed ID: 12077088
[TBL] [Abstract][Full Text] [Related]
7. ISIS 2302. Oligo-TCS.
Drugs R D; 1999 Mar; 1(3):265-7. PubMed ID: 10566042
[No Abstract] [Full Text] [Related]
8. Therapeutic approaches in inflammatory bowel disease based on the immunopathogenesis.
Siegmund B; Zeitz M
Rocz Akad Med Bialymst; 2004; 49():22-30. PubMed ID: 15631310
[TBL] [Abstract][Full Text] [Related]
9. A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis.
van Deventer SJ; Tami JA; Wedel MK
Gut; 2004 Nov; 53(11):1646-51. PubMed ID: 15479686
[TBL] [Abstract][Full Text] [Related]
10. Antiadhesion molecule therapy in inflammatory bowel disease.
van Assche G; Rutgeerts P
Inflamm Bowel Dis; 2002 Jul; 8(4):291-300. PubMed ID: 12131614
[TBL] [Abstract][Full Text] [Related]
11. Technology evaluation: alicaforsen (Isis).
Gewirtz AT; Sitaraman SV
Curr Opin Mol Ther; 2005 Jun; 7(3):273-81. PubMed ID: 15977426
[TBL] [Abstract][Full Text] [Related]
12. Targeting Endothelial Ligands: ICAM-1/alicaforsen, MAdCAM-1.
Reinisch W; Hung K; Hassan-Zahraee M; Cataldi F
J Crohns Colitis; 2018 Aug; 12(suppl_2):S669-S677. PubMed ID: 29757363
[TBL] [Abstract][Full Text] [Related]
13. Past, Present and Future of Therapeutic Interventions Targeting Leukocyte Trafficking in Inflammatory Bowel Disease.
Panés J; Salas A
J Crohns Colitis; 2018 Aug; 12(suppl_2):S633-S640. PubMed ID: 30137311
[TBL] [Abstract][Full Text] [Related]
14. Gene polymorphisms and serological markers of patients with active Crohn's disease in a clinical trial of antisense to ICAM-1.
Yacyshyn BR; Schievella A; Sewell KL; Tami JA
Clin Exp Immunol; 2005 Jul; 141(1):141-7. PubMed ID: 15958080
[TBL] [Abstract][Full Text] [Related]
15. Antisense oligonucleotide treatment of inflammatory bowel diseases.
Yacyshyn BR
Methods Mol Med; 2005; 106():295-305. PubMed ID: 15375323
[No Abstract] [Full Text] [Related]
16. Safety of biologic therapy.
Blonski W; Lichtenstein GR
Inflamm Bowel Dis; 2007 Jun; 13(6):769-96. PubMed ID: 17304581
[TBL] [Abstract][Full Text] [Related]
17. Alicaforsen for the treatment of inflammatory bowel disease.
Jairath V; Khanna R; Feagan BG
Expert Opin Investig Drugs; 2017 Aug; 26(8):991-997. PubMed ID: 28670932
[TBL] [Abstract][Full Text] [Related]
18. Antisense inhibition of ICAM-1 expression as therapy provides insight into basic inflammatory pathways through early experiences in IBD.
Philpott JR; Miner PB
Expert Opin Biol Ther; 2008 Oct; 8(10):1627-32. PubMed ID: 18774928
[TBL] [Abstract][Full Text] [Related]
19. Biologic therapy for inflammatory bowel disease.
Ardizzone S; Bianchi Porro G
Drugs; 2005; 65(16):2253-86. PubMed ID: 16266194
[TBL] [Abstract][Full Text] [Related]
20. Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis.
Miner PB; Geary RS; Matson J; Chuang E; Xia S; Baker BF; Wedel MK
Aliment Pharmacol Ther; 2006 May; 23(10):1427-34. PubMed ID: 16669957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
